Compare · ARGX vs CVM
ARGX vs CVM
Side-by-side comparison of argenx SE (ARGX) and Cel-Sci Corporation (CVM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and CVM operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.83B, about 2254.1x CVM ($28.3M).
- Both names hit the wire about 10 times in the past 4 weeks.
- ARGX has more recent analyst coverage (25 ratings vs 0 for CVM).
- Company
- argenx SE
- Cel-Sci Corporation
- Price
- -
- -
- Market cap
- $63.83B
- $28.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 2017
- 1997
- News (4w)
- 10
- 10
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Cel-Sci Corporation
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Latest ARGX
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Completes Acquisition of Forte Biosciences, Inc.
- argenx upgraded by UBS with a new price target
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Latest CVM
- Chief Executive Officer Kersten Geert R bought $138,000 worth of shares (100,000 units at $1.38), increasing direct ownership by 46% to 316,142 units (SEC Form 4)
- SEC Form 4 filed by Director Watson Robert Eugene
- SEC Form 4 filed by Director Baillavoine Bruno Jean-Marie
- SEC Form 4 filed by Senior Vice President Cipriano John
- SEC Form 4 filed by Chief Scientific Officer Talor Eyal
- SEC Form 4 filed by Chief Financial Officer Prichep Patricia B
- SEC Form 4 filed by Chief Executive Officer Kersten Geert R
- Cel-Sci Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CEL-SCI Reports Fiscal Third Quarter 2026 Results
- SEC Form 10-Q filed by Cel-Sci Corporation